Purpose: The study aimed to evaluate the impact of a collaborative medical-pharmacist clinical support tool on managing patients diagnosed with Peripheral Arterial Disease (PAD). Consensus guidelines recommend antiplatelet and statin therapy alongside optimisation of blood pressure, diabetes management, and smoking cessation. Despite an evident reduction in all-cause mortality, cardiovascular, cerebrovascular, critical limb events and disease progression, adoption of these interventions is suboptimal. Methodology: A retrospective cohort study was conducted to evaluate the impact of a new clinical decision support tool on optimising best medical therapy in PAD patients (≥18 years) admitted under the vascular unit in a metropolitan hospital. Pre-intervention phase was conducted in April-June 2021. Post-intervention phase was conducted in September-November 2021. Antiplatelet, statin, and antihypertensive prescribing, HbA1c monitoring, and referral to smoking cessation services were reviewed. Data was summarised using descriptive statistics, and inferential statistical analyses were performed to assess the intervention's impact on optimising PAD management. Results: A total of 168 patients were included: 97(58%) pre-intervention group, and 71(42%) post-intervention group. 63(38%) had concurrent diabetes (26pre vs. 37post) and 56(33%) smoked (35pre vs. 21post). Optimal prescribing of antiplatelets, statins (atorvastatin≥40mg) and antihypertensives increased post-intervention (73(75%) vs. 59(83%), p=0.22; 57(59%) vs. 54(76%), p=0.019 and 65(67%) vs. 53(75%), p=0.29, respectively). Monitoring of HbA1c increased from 1/26(4%) to 26/37(70%) (p<0.01). All 56 smokers received smoking cessation counselling. Conclusion: Collaborative medical-pharmacist approach improved optimal statin dosing and HbA1c monitoring, underscoring the value of targeting interventions in improving PAD management. Long-term follow-up of clinical outcomes is required.